Entry Point Capital, LLC Bio N Tech Se Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNTX
# of Institutions
329Shares Held
38.8MCall Options Held
844KPut Options Held
1.4M-
Baillie Gifford & CO8.31MShares$883 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$480 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$464 Million2.05% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.93MShares$311 Million1.34% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$202 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.8B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...